GNI Group   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (2001)

Organization Overview

First Clinical Trial
2015
NCT02296281
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Continent Pharmaceutical Co, Ltd. | GNI-EPS Pharmaceuticals, Inc. (GNI Group)